Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents
<p>In this paper analysis of anemia correction efficacy in multiple myeloma patients was shown. Patients (n = 68) treated with epoetin alfa (recombinant erythropoietin (rEPO)) 150 IU/kg subcutaneously three times per week (no more 20 weeks) were included in the study group. Patients who did no...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | http://oncohematology.abvpress.ru/index.php/ongm/article/view/58 |
| _version_ | 1811173668382834688 |
|---|---|
| author | N. A. Romanenko N. A. Potikhonova K. M. Abdulkadyrov |
| author_facet | N. A. Romanenko N. A. Potikhonova K. M. Abdulkadyrov |
| author_sort | N. A. Romanenko |
| collection | DOAJ |
| description | <p>In this paper analysis of anemia correction efficacy in multiple myeloma patients was shown. Patients (n = 68) treated with epoetin alfa (recombinant erythropoietin (rEPO)) 150 IU/kg subcutaneously three times per week (no more 20 weeks) were included in the study group. Patients who did not receive erythropoiesis-stimulating therapy were included in the control group (n = 31). Patients in both groups received at least 3 courses of chemotherapy and continued to receive anticancer treatment during follow-up. Baseline hemoglobin level was 5.3 g/dl – 10.0 g/dl. The increase in hemoglobin level to normal range (≥ 12.0 g/dl) during ≤ 20 weeks was considered as positive therapy response. Positive response rate was higher in patients received epoetin alfa comparing with control group (64.7 % and 25.8 %, respectively; p < 0.05). Transfusion dependence persisted in 6 from 19 study patients who received RBC transfusions along with rEPO therapy (31.6 %), whereas in 5 from 9 control group patients (55.6 %). In epoetin alfa group significant increase in reticulocytes count at 2–3 weeks of therapy<br />was revealed: from 27.3 × 109/l to 64.9 × 109/l (in patients with positive response) and from 13.3 × 109/l to 25.1 × 109/l (in patients without response). Changes in the reticulocytes count in the control group were not revealed. Thus in patients with positive response reticulocytes level significantly increased to 3 weeks of therapy compared with negative response patients (37.6 × 109/l versus 11.8 × 109/l, respectively; p < 0,05), it can be used as prognostic factors of rEPO response.</p> |
| first_indexed | 2024-04-10T17:50:53Z |
| format | Article |
| id | doaj.art-78861257064a411a89d5ecb2ac582d37 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 |
| language | Russian |
| last_indexed | 2024-04-10T17:50:53Z |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-78861257064a411a89d5ecb2ac582d372023-02-02T21:22:09ZrusABV-pressОнкогематология1818-83462014-07-0172222773Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agentsN. A. Romanenko0N. A. Potikhonova1K. M. Abdulkadyrov2Russian Research Institute of Hematology and Transfusiology, Russian Federal Medical-biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medical-biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medical-biological Agency<p>In this paper analysis of anemia correction efficacy in multiple myeloma patients was shown. Patients (n = 68) treated with epoetin alfa (recombinant erythropoietin (rEPO)) 150 IU/kg subcutaneously three times per week (no more 20 weeks) were included in the study group. Patients who did not receive erythropoiesis-stimulating therapy were included in the control group (n = 31). Patients in both groups received at least 3 courses of chemotherapy and continued to receive anticancer treatment during follow-up. Baseline hemoglobin level was 5.3 g/dl – 10.0 g/dl. The increase in hemoglobin level to normal range (≥ 12.0 g/dl) during ≤ 20 weeks was considered as positive therapy response. Positive response rate was higher in patients received epoetin alfa comparing with control group (64.7 % and 25.8 %, respectively; p < 0.05). Transfusion dependence persisted in 6 from 19 study patients who received RBC transfusions along with rEPO therapy (31.6 %), whereas in 5 from 9 control group patients (55.6 %). In epoetin alfa group significant increase in reticulocytes count at 2–3 weeks of therapy<br />was revealed: from 27.3 × 109/l to 64.9 × 109/l (in patients with positive response) and from 13.3 × 109/l to 25.1 × 109/l (in patients without response). Changes in the reticulocytes count in the control group were not revealed. Thus in patients with positive response reticulocytes level significantly increased to 3 weeks of therapy compared with negative response patients (37.6 × 109/l versus 11.8 × 109/l, respectively; p < 0,05), it can be used as prognostic factors of rEPO response.</p>http://oncohematology.abvpress.ru/index.php/ongm/article/view/58erythropoietinepoietin alphareticulocytehemoglobinanemiamultiple myelomared blood cells transfusion |
| spellingShingle | N. A. Romanenko N. A. Potikhonova K. M. Abdulkadyrov Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents Онкогематология erythropoietin epoietin alpha reticulocyte hemoglobin anemia multiple myeloma red blood cells transfusion |
| title | Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents |
| title_full | Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents |
| title_fullStr | Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents |
| title_full_unstemmed | Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents |
| title_short | Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents |
| title_sort | correction of anemia in multiple myeloma patients by erythropoiesis stimulating agents |
| topic | erythropoietin epoietin alpha reticulocyte hemoglobin anemia multiple myeloma red blood cells transfusion |
| url | http://oncohematology.abvpress.ru/index.php/ongm/article/view/58 |
| work_keys_str_mv | AT naromanenko correctionofanemiainmultiplemyelomapatientsbyerythropoiesisstimulatingagents AT napotikhonova correctionofanemiainmultiplemyelomapatientsbyerythropoiesisstimulatingagents AT kmabdulkadyrov correctionofanemiainmultiplemyelomapatientsbyerythropoiesisstimulatingagents |